These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39135171)

  • 21. Performance of the EQ-5D in patients with irritable bowel syndrome.
    Bushnell DM; Martin ML; Ricci JF; Bracco A
    Value Health; 2006; 9(2):90-7. PubMed ID: 16626412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D.
    Walters SJ; Brazier JE
    Qual Life Res; 2005 Aug; 14(6):1523-32. PubMed ID: 16110932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
    McClure NS; Sayah FA; Xie F; Luo N; Johnson JA
    Value Health; 2017 Apr; 20(4):644-650. PubMed ID: 28408007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient characteristics and valuation changes impact quality of life and satisfaction in total knee arthroplasty - results from a German prospective cohort study.
    Felix J; Becker C; Vogl M; Buschner P; Plötz W; Leidl R
    Health Qual Life Outcomes; 2019 Dec; 17(1):180. PubMed ID: 31815627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany.
    Stark RG; Reitmeir P; Leidl R; König HH
    Inflamm Bowel Dis; 2010 Jan; 16(1):42-51. PubMed ID: 19475674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
    Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
    Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The responsiveness of EQ-5D utility scores in patients with depression: A comparison with instruments measuring quality of life, psychopathology and social functioning.
    Günther OH; Roick C; Angermeyer MC; König HH
    J Affect Disord; 2008 Jan; 105(1-3):81-91. PubMed ID: 17532051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany.
    Klapproth CP; Sidey-Gibbons CJ; Valderas JM; Rose M; Fischer F
    Value Health; 2022 May; 25(5):824-834. PubMed ID: 35500951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease.
    Tsai APY; Hur SA; Wong A; Safavi M; Assayag D; Johannson KA; Morisset J; Fell C; Fisher JH; Manganas H; Shapera S; Cox G; Gershon AS; Hambly N; Khalil N; To T; Wilcox PG; Halayko A; Kolb MR; Ryerson CJ
    Thorax; 2021 Jan; 76(1):37-43. PubMed ID: 33023996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions.
    Sola-Morales O; Curtis LH; Heidt J; Walsh L; Casso D; Oliveria S; Saunders-Hastings P; Song Y; Mercado T; Zusterzeel R; Mastey V; Harnett J; Quek RGW
    Clin Pharmacol Ther; 2023 Aug; 114(2):325-355. PubMed ID: 37079433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life assessment in patients with heart failure: validity of the German version of the generic EQ-5D-5L™.
    Boczor S; Daubmann A; Eisele M; Blozik E; Scherer M
    BMC Public Health; 2019 Nov; 19(1):1464. PubMed ID: 31694584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the magnitude of injuries affect the outcome of proximal humerus fractures treated by locked plating (PHILOS)?
    Berk T; Halvachizadeh S; Bellmann F; Büsser L; Pape HC; Allemann F
    Eur J Trauma Emerg Surg; 2022 Dec; 48(6):4515-4522. PubMed ID: 32778927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
    Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
    Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation.
    Chen P; Lin KC; Liing RJ; Wu CY; Chen CL; Chang KC
    Qual Life Res; 2016 Jun; 25(6):1585-96. PubMed ID: 26714699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.
    Criscitiello C; Spurden D; Piercy J; Rider A; Williams R; Mitra D; Wild R; Corsaro M; Kurosky SK; Law EH
    Clin Ther; 2021 Jul; 43(7):1228-1244.e4. PubMed ID: 34256965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EQ-5D in Central and Eastern Europe: 2000-2015.
    Rencz F; Gulácsi L; Drummond M; Golicki D; Prevolnik Rupel V; Simon J; Stolk EA; Brodszky V; Baji P; Závada J; Petrova G; Rotar A; Péntek M
    Qual Life Res; 2016 Nov; 25(11):2693-2710. PubMed ID: 27472992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EQ-5D-3L health status and health state utilities of the oldest-old (85 +) in Germany: results from the AgeCoDe-AgeQualiDe study.
    König HH; Brettschneider C; Lühmann D; Kaduszkiewicz H; Oey A; Wiese B; Werle J; Weyerer S; Fuchs A; Pentzek M; Conrad I; Röhr S; Weeg D; Bickel H; Heser K; Wagner M; Scherer M; Maier W; Riedel-Heller SG; Hajek A
    Qual Life Res; 2020 Dec; 29(12):3223-3232. PubMed ID: 32851600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The remarkably frequent use of EQ-5D in non-economic research.
    Wang A; Rand K; Yang Z; Brooks R; Busschbach J
    Eur J Health Econ; 2022 Aug; 23(6):1007-1014. PubMed ID: 34846623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders.
    König HH; Roick C; Angermeyer MC
    Eur Psychiatry; 2007 Apr; 22(3):177-87. PubMed ID: 17142014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.